US Pharma MarketingAlzheimer's drug rollout letdown, a China-based heart drug startup, and more biotech news from The Readout Physicians FDA research Newsletters Log In My Account Subscribe Now My Account Settings Complete your personal information for a more tailored experience Billing Log Out A decade of reporting from the frontiers of health and medicine Newsletters Log In My Account Subscribe Now Biotech Pharma Public Health Health Tech Policy Science First Opinion STAT+ STAT Events Search Log In Try STAT+ My Account Home Newsletter The Readout Astellas treatment offers new hope to a devastated rare disease community Alzheimer’s drug rollout letdown, a China-based…
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
There’s fresh turmoil at the very top of the FDA: All weekend, questions have swirled over whether Commissioner Marty Makary will be ousted.
Also, we have a resurrected gene therapy effort in a once-devastated rare disease program, and underwhelming Alzheimer’s drug adoption.
Source: STAT News Pharma